Wanbury's Tanuku plant at Andhra Pradesh successfully completes ANVISA inspection

Wanbury's Tanuku plant at Andhra Pradesh successfully completed ANVISA inspection (Brazil Health Regulatory Agency) started from 16.12.2024 to 19.12.2024 (4 days) for its API manufacturing facility. Inspection completed with zero observations which means no observation during the inspection process for 5 APIs confirming strict adherence of cGMP practices at its state-of-the-art API manufacturing facility. The Company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe since ANVISA (Agenica National De Vigilancia Sanitaria) is part of PIC (Pharmaceutical Inspection Convention).

This is second international FDA inspection with zero observations this year after US FDA inspection completed in June 2024 at Patalganga plant also with zero observations.

Wanbury is one of the largest manufacturer of Metformin HCI & Sertraline API in addition to other API' s with few more are under final stage of development & set to be produced shortly in the said facility. This inspection validates management continued commitment to Quality of the APis as per international regulations.

Shares of Wanbury Limited was last trading in BSE at Rs. 290.05 as compared to the previous close of Rs. 305.30. The total number of shares traded during the day was 132582 in over 620 trades.

The stock hit an intraday high of Rs. 294.80 and intraday low of 290.05. The net turnover during the day was Rs. 38485239.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 TanukuPlant AndhraPradesh ANVISA Inspection